Pfizer Inc. could have resulted from its late-stage coronavirus vaccine trial available as early as October.
According to CEO Albert Bourla, “The pharmaceutical company has already enrolled 23,000 volunteers in the phase three trial that began in late July.”
It hopes to enroll at least 30,000 participants between the ages of 18 and 85 across 120 sites globally.
“We expect by the end of October, we should have enough … to say whether the product works or not,” he added.
The New York-based drug company says if data shows the jab is safe and effective, it will submit an application for approval, along with its German partner BioNTech, immediately.
Pfizer’s potential vaccine is one of three backed by the U.S. that’s currently in late-stage testing. The U.S.-based pharmaceutical giant has been working alongside German drugmaker BioNTech.
The companies’ experimental vaccine contains genetic material called messenger RNA, or mRNA. In July, the company released promising data from its early-stage trial.
If it is successful, they expect to submit it for the final regulatory review as early as October. They plan to supply up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021.